3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Colorectal Neoplasms
22
Neoplasms
13
Colonic Neoplasms
10
Breast Neoplasms
10
Venous Thromboembolism
8
Prostatic Neoplasms
8
Multiple Myeloma
7
Recurrence
6
Polycythemia Vera
6
Carcinoma, Non-Small-Cell Lung
6
Thrombocythemia, Essential
4
Neoplasms, Plasma Cell
4
Ovarian Neoplasms
3
Neoplasm Metastasis
3
Melanoma
3
Thrombosis
2
Sarcoma
2
Rectal Neoplasms
2
Primary Myelofibrosis
2
Pancreatic Neoplasms
2
Neoplastic Cells, Circulating
2
Neoplasms by Site
2
Myocardial Infarction
2
Lung Neoplasms
2
Intestinal Neoplasms
2
Intestinal Diseases
2
Inflammation
2
Gastrointestinal Neoplasms
2
Fallopian Tube Neoplasms
2
Esophageal Neoplasms
2
Interventions
Cisplatin
21
pembrolizumab
16
Gemcitabine
16
Paclitaxel
15
Radiotherapy
14
Carboplatin
14
Radiotherapy, Intensity-Modulated
13
Cyclophosphamide
9
Cetuximab
9
Magnetic Resonance Spectroscopy
8
Radiation
7
padeliporfin
6
Specimen Handling
6
Oxaliplatin
6
Fluorouracil
6
Drug Therapy
6
Docetaxel
6
Capecitabine
6
Bevacizumab
6
anlotinib
5
Nivolumab
5
Irinotecan
5
Erlotinib Hydrochloride
5
Celecoxib
5
poly ICLC
4
fludarabine
4
Standard of Care
4
Sorafenib
4
Leucovorin
4
Ipilimumab
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Carcinoma
×
Aspirin
×
Clear all
NCT07529262
2026-04-14
AspiRe HCC
Curtin University
Phase 3
Not yet recruiting
890 enrolled